Charles River Laboratories International, Inc.

CRL · NYSE · Stock · Healthcare
$303.60
+1.53% today
Delayed price,

What Charles River Laboratories International does

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Key facts

Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$14.62B
P/E (ttm)
—
Forward P/E
23.8
Dividend yield
0.00%
Beta
1.40
Profit margin
-6.0%
Employees
18,300
Headquarters
Wilmington, MA, United States
Exchange
NYSE

Performance

1 Month
+9.2%
3 Months
+35.3%
6 Months
+65.1%
1 Year
+70.1%
5 Years
-17.0%
$146.2052-week range$333.30
Biggest setback — last 12 months
-31.7%
5 Jan 2026 → 11 May 2026
Fell from $220.91 to $150.85 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+101.3%
11 May 2026 → 14 Oct 2026
Ran from $150.85 to $303.60 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$268.06 (-11.7%)$303.60$343.85 (+13.3%)
3 Months$244.71 (-19.4%)$303.60$376.67 (+24.1%)
6 Months$223.80 (-26.3%)$303.60$411.86 (+35.7%)
12 Months$197.24 (-35.0%)$303.60$467.31 (+53.9%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 43.1%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 10 shares at $297.43 — Coleman Glenn, EVP & Chief Financial Officer · 2026-10-02
Sold 67,122 shares at $300.00 — FOSTER JAMES C, Director · 2026-08-27
Sold 528 shares — Girshick Birgit, Chief Executive Officer · 2026-08-20
Sold 4,078 shares at $294.12 — Parisotto Shannon M, CEVP, Disc & Safety Assessment · 2026-08-20
Sold 1,146 shares at $285.24 — Andrews Nancy C, Director · 2026-08-20
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.